{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:15:37Z","timestamp":1787166937323,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2019J01151"],"award-info":[{"award-number":["2019J01151"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022CXA014"],"award-info":[{"award-number":["2022CXA014"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fujian province Joint Funds for the innovation of science and Technology","award":["2019Y9060"],"award-info":[{"award-number":["2019Y9060"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Chemoresistance is a major challenge for acute lymphoblastic leukemia (ALL) treatment. Cysteine-rich protein 61 (Cyr61) plays an important role in drug resistance modulation of tumor cells, and Cyr61 levels are increased in the bone marrow of patients with ALL and contribute to ALL cell survival. However, the effect of Cyr61 on B cell acute lymphoblastic leukemia (B-ALL) cell chemosensitivity and the regulatory mechanisms underlying Cyr61 production in bone marrow remain unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nalm-6 and Reh human B-ALL cell lines were used in this study. Cyr61 levels were assessed using quantitative real-time PCR (qRT-PCR), western blot analysis, and enzyme-linked immunosorbent assay. The effect of Cyr61 on B-ALL cell chemosensitivity to daunorubicin (DNR) was evaluated using cell viability and flow cytometry analyses. The regulatory mechanisms of Cyr61 production in bone marrow were examined using qRT-PCR and western blot analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Cyr61 knockdown and overexpression increased and decreased the chemosensitivity of B-ALL cells to DNR, respectively. Cyr61 attenuated chemotherapeutic drug-induced apoptosis by upregulating B cell lymphoma-2. Notably, DNR induced DNA damage response and increased Cyr61 secretion in B-ALL cells through the ataxia telangiectasia mutated (ATM)-dependent nuclear factor kappa B pathway.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DNR induces Cyr61 production in B-ALL cells, and increased Cyr61 levels reduce the chemosensitivity of B-ALL cells. Consequently, targeting Cyr61 or related ATM signaling pathway may present a promising treatment strategy to enhance the chemosensitivity of patients with B-ALL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00432-024-05692-8","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T06:02:02Z","timestamp":1711432922000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity"],"prefix":"10.1007","volume":"150","author":[{"given":"Pengchong","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaozhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglu","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingping","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"issue":"1","key":"5692_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.cell.2012.04.042","volume":"150","author":"S Acharyya","year":"2012","unstructured":"Acharyya S, Oskarsson T, Vanharanta S, Malladi S, Kim J, Morris PG, Manova-Todorova K, Leversha M, Hogg N, Seshan VE et al (2012) A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 150(1):165\u2013178. https:\/\/doi.org\/10.1016\/j.cell.2012.04.042","journal-title":"Cell"},{"issue":"1","key":"5692_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.it.2013.10.002","volume":"35","author":"BA Anthony","year":"2014","unstructured":"Anthony BA, Link DC (2014) Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol 35(1):32\u201337. https:\/\/doi.org\/10.1016\/j.it.2013.10.002","journal-title":"Trends Immunol"},{"issue":"5","key":"5692_CR3","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1529\/biophysj.105.068122","volume":"90","author":"EZ Bagci","year":"2006","unstructured":"Bagci EZ, Vodovotz Y, Billiar TR, Ermentrout GB, Bahar I (2006) Bistability in apoptosis: roles of bax, bcl-2, and mitochondrial permeability transition pores. Biophys J 90(5):1546\u20131559. https:\/\/doi.org\/10.1529\/biophysj.105.068122","journal-title":"Biophys J"},{"issue":"2","key":"5692_CR4","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.3892\/ijmm.2018.4018","volume":"43","author":"Y Cao","year":"2019","unstructured":"Cao Y, Wu C, Song Y, Lin Z, Kang Y, Lu P, Zhang C, Huang Q, Hao T, Zhu X, Hu J (2019) Cyr61 decreases cytarabine chemosensitivity in acute lymphoblastic leukemia cells via NF-\u03baB pathway activation. Int J Mol Med 43(2):1011\u20131020. https:\/\/doi.org\/10.3892\/ijmm.2018.4018","journal-title":"Int J Mol Med"},{"issue":"10","key":"5692_CR5","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1038\/s41375-019-0458-0","volume":"33","author":"YL Chen","year":"2019","unstructured":"Chen YL, Tang C, Zhang MY, Huang WL, Xu Y, Sun HY, Yang F, Song LL, Wang H, Mu LL et al (2019) Blocking ATM-dependent NF-\u03baB pathway overcomes niche protection and improves chemotherapy response in acute lymphoblastic leukemia. Leukemia 33(10):2365\u20132378. https:\/\/doi.org\/10.1038\/s41375-019-0458-0","journal-title":"Leukemia"},{"issue":"23","key":"5692_CR6","doi-asserted-by":"publisher","first-page":"5908","DOI":"10.1158\/1078-0432.CCR-10-1200","volume":"16","author":"KB D\u2019Antonio","year":"2010","unstructured":"D\u2019Antonio KB, Schultz L, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH (2010) Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clin Cancer Res 16(23):5908\u20135913. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-1200","journal-title":"Clin Cancer Res"},{"issue":"6","key":"5692_CR7","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.ccr.2014.04.015","volume":"25","author":"CW Duan","year":"2014","unstructured":"Duan CW, Shi J, Chen J, Wang B, Yu YH, Qin X, Zhou XC, Cai YJ, Li ZQ, Zhang F et al (2014) Leukemia propagating cells rebuild an evolving niche in response to therapy. Cancer Cell 25(6):778\u2013793. https:\/\/doi.org\/10.1016\/j.ccr.2014.04.015","journal-title":"Cancer Cell"},{"issue":"10","key":"5692_CR8","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00432-013-1476-3","volume":"139","author":"J Esparza-L\u00f3pez","year":"2013","unstructured":"Esparza-L\u00f3pez J, Medina-Franco H, Escobar-Arriaga E, Le\u00f3n-Rodr\u00edguez E, Zentella-Dehesa A, Ibarra-S\u00e1nchez MJ (2013) Doxorubicin induces atypical NF-\u03baB activation through c-Abl kinase activity in breast cancer cells. J Cancer Res Clin Oncol 139(10):1625\u20131635. https:\/\/doi.org\/10.1007\/s00432-013-1476-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"5692_CR9","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.3892\/or.2014.3131","volume":"31","author":"XJ Fang","year":"2014","unstructured":"Fang XJ, Jiang H, Zhu YQ, Zhang LY, Fan QH, Tian Y (2014) Doxorubicin induces drug resistance and expression of the novel CD44st via NF-\u03baB in human breast cancer MCF-7 cells. Oncol Rep 31(6):2735\u20132742. https:\/\/doi.org\/10.3892\/or.2014.3131","journal-title":"Oncol Rep"},{"key":"5692_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41421-017-0005-y","volume":"4","author":"M Gao","year":"2018","unstructured":"Gao M, Chen M, Li C, Xu M, Liu Y, Cong M, Sang N, Liu S (2018) Long non-coding RNA MT1DP shunts the cellular defense to cytotoxicity through crosstalk with MT1H and RhoC in cadmium stress. Cell Discov 4:5. https:\/\/doi.org\/10.1038\/s41421-017-0005-y","journal-title":"Cell Discov"},{"key":"5692_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12935-016-0326-1","volume":"16","author":"H Garg","year":"2016","unstructured":"Garg H, Suri P, Gupta JC, Talwar GP, Dubey S (2016) Survivin: a unique target for tumor therapy. Cancer Cell Int 16:49. https:\/\/doi.org\/10.1186\/s12935-016-0326-1","journal-title":"Cancer Cell Int"},{"issue":"20","key":"5692_CR12","doi-asserted-by":"publisher","first-page":"7243","DOI":"10.1158\/1078-0432.CCR-05-0231","volume":"11","author":"S Gery","year":"2005","unstructured":"Gery S, Xie D, Yin D, Gabra H, Miller C, Wang H, Scott D, Yi WS, Popoviciu ML, Said JW, Koeffler HP (2005) Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells. Clin Cancer Res 11(20):7243\u20137254. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0231","journal-title":"Clin Cancer Res"},{"issue":"3","key":"5692_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cell.2010.09.043","volume":"143","author":"LA Gilbert","year":"2010","unstructured":"Gilbert LA, Hemann MT (2010) DNA damage-mediated induction of a chemoresistant niche. Cell 143(3):355\u2013366. https:\/\/doi.org\/10.1016\/j.cell.2010.09.043","journal-title":"Cell"},{"issue":"7","key":"5692_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1158\/1541-7786.MCR-16-0387","volume":"15","author":"L Gomez-Sarosi","year":"2017","unstructured":"Gomez-Sarosi L, Sun Y, Coleman I, Bianchi-Frias D, Nelson PS (2017) DNA damage induces a secretory program in the quiescent TME that fosters adverse cancer phenotypes. Mol Cancer Res 15(7):842\u2013851. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0387","journal-title":"Mol Cancer Res"},{"issue":"27","key":"5692_CR15","doi-asserted-by":"publisher","first-page":"44465","DOI":"10.18632\/oncotarget.17973","volume":"8","author":"B Guo","year":"2017","unstructured":"Guo B, Li L, Guo J, Liu A, Wu J, Wang H, Shi J, Pang D, Cao Q (2017) M2 tumor-associated macrophages produce interleukin-17 to suppress oxaliplatin-induced apoptosis in hepatocellular carcinoma. Oncotarget 8(27):44465\u201344476. https:\/\/doi.org\/10.18632\/oncotarget.17973","journal-title":"Oncotarget"},{"issue":"47","key":"5692_CR16","doi-asserted-by":"publisher","first-page":"7396","DOI":"10.1038\/sj.onc.1206943","volume":"22","author":"LA Hazlehurst","year":"2003","unstructured":"Hazlehurst LA, Landowski TH, Dalton WS (2003) Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death. Oncogene 22(47):7396\u20137402. https:\/\/doi.org\/10.1038\/sj.onc.1206943","journal-title":"Oncogene"},{"key":"5692_CR17","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.3389\/fonc.2019.01074","volume":"9","author":"JW Hellinger","year":"2019","unstructured":"Hellinger JW, H\u00fcchel S, Goetz L, Bauerschmitz G, Emons G, Gr\u00fcndker C (2019) Inhibition of CYR61-S100A4 axis limits breast cancer invasion. Front Oncol 9:1074. https:\/\/doi.org\/10.3389\/fonc.2019.01074","journal-title":"Front Oncol"},{"issue":"11","key":"5692_CR18","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/carcin\/bgw093","volume":"37","author":"RA Hesler","year":"2016","unstructured":"Hesler RA, Huang JJ, Starr MD, Treboschi VM, Bernanke AG, Nixon AB, McCall SJ, White RR, Blobe GC (2016) TGF-\u03b2-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3. Carcinogenesis 37(11):1041\u20131051. https:\/\/doi.org\/10.1093\/carcin\/bgw093","journal-title":"Carcinogenesis"},{"issue":"7","key":"5692_CR19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/35080103","volume":"2","author":"M Holcik","year":"2001","unstructured":"Holcik M, Korneluk RG (2001) XIAP, the guardian angel. Nat Rev Mol Cell Biol 2(7):550\u2013556. https:\/\/doi.org\/10.1038\/35080103","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"5692_CR20","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.18632\/oncotarget.3040","volume":"6","author":"RM Huber","year":"2015","unstructured":"Huber RM, Lucas JM, Gomez-Sarosi LA, Coleman I, Zhao S, Coleman R, Nelson PS (2015) DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. Oncotarget 6(4):2134\u20132147. https:\/\/doi.org\/10.18632\/oncotarget.3040","journal-title":"Oncotarget"},{"key":"5692_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22084259","author":"MB Ismail","year":"2021","unstructured":"Ismail MB, Rajendran P, AbuZahra HM, Veeraraghavan VP (2021) Mangiferin inhibits apoptosis in doxorubicin-induced vascular endothelial cells via the Nrf2 signaling pathway. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22084259","journal-title":"Int J Mol Sci"},{"issue":"15","key":"5692_CR22","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1002\/cncr.29383","volume":"121","author":"E Jabbour","year":"2015","unstructured":"Jabbour E, O\u2019Brien S, Konopleva M, Kantarjian H (2015) New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 121(15):2517\u20132528. https:\/\/doi.org\/10.1002\/cncr.29383","journal-title":"Cancer"},{"key":"5692_CR23","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/1471-2407-14-164","volume":"14","author":"D Jeong","year":"2014","unstructured":"Jeong D, Heo S, Sung Ahn T, Lee S, Park S, Kim H, Park D, Byung Bae S, Lee SS, Soo Lee M et al (2014) Cyr61 expression is associated with prognosis in patients with colorectal cancer. BMC Cancer 14:164. https:\/\/doi.org\/10.1186\/1471-2407-14-164","journal-title":"BMC Cancer"},{"issue":"4","key":"5692_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1677\/erc.1.00825","volume":"11","author":"WG Jiang","year":"2004","unstructured":"Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE (2004) Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. EndocrRelat Cancer 11(4):781\u2013791. https:\/\/doi.org\/10.1677\/erc.1.00825","journal-title":"EndocrRelat Cancer"},{"issue":"1","key":"5692_CR25","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/cdd.2017.186","volume":"25","author":"J Kale","year":"2018","unstructured":"Kale J, Osterlund EJ, Andrews DW (2018) BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25(1):65\u201380. https:\/\/doi.org\/10.1038\/cdd.2017.186","journal-title":"Cell Death Differ"},{"issue":"12","key":"5692_CR26","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1002\/hed.21381","volume":"32","author":"SH Kok","year":"2010","unstructured":"Kok SH, Chang HH, Tsai JY, Hung HC, Lin CY, Chiang CP, Liu CM, Kuo MY-P (2010) Expression of Cyr61 (CCN1) in human oral squamous cell carcinoma: an independent marker for poor prognosis. Head Neck 32(12):1665\u20131673. https:\/\/doi.org\/10.1002\/hed.21381","journal-title":"Head Neck"},{"issue":"1","key":"5692_CR27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2011.10.016","volume":"315","author":"KB Lee","year":"2012","unstructured":"Lee KB, Byun HJ, Park SH, Park CY, Lee SH, Rho SB (2012) CYR61 controls p53 and NF-kappaB expression through PI3K\/Akt\/mTOR pathways in carboplatin-induced ovarian cancer cells. Cancer Lett 315(1):86\u201395. https:\/\/doi.org\/10.1016\/j.canlet.2011.10.016","journal-title":"Cancer Lett"},{"issue":"5","key":"5692_CR28","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.21873\/anticanres.12520","volume":"38","author":"JJ Lee","year":"2018","unstructured":"Lee JJ, Koh KN, Park CJ, Jang S, Im HJ, Kim N (2018) The combination of flavokawain B and daunorubicin induces apoptosis in human myeloid leukemic cells by modifying NF-\u03baB. Anticancer Res 38(5):2771\u20132778. https:\/\/doi.org\/10.21873\/anticanres.12520","journal-title":"Anticancer Res"},{"issue":"23","key":"5692_CR29","doi-asserted-by":"publisher","first-page":"24015","DOI":"10.1074\/jbc.M402305200","volume":"279","author":"MT Lin","year":"2004","unstructured":"Lin MT, Chang CC, Chen ST, Chang HL, Su JL, Chau YP, Kuo ML (2004) Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem 279(23):24015\u201324023. https:\/\/doi.org\/10.1074\/jbc.M402305200","journal-title":"J Biol Chem"},{"issue":"16","key":"5692_CR30","doi-asserted-by":"publisher","first-page":"5809","DOI":"10.1158\/1078-0432.CCR-04-2639","volume":"11","author":"MT Lin","year":"2005","unstructured":"Lin MT, Zuon CY, Chang CC, Chen ST, Chen CP, Lin BR, Wang MY, Jeng YM, Chang KJ, Lee PH et al (2005) Cyr61 induces gastric cancer cell motility\/invasion via activation of the integrin\/nuclear factor-kappaB\/cyclooxygenase-2 signaling pathway. Clin Cancer Res 11(16):5809\u20135820. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-2639","journal-title":"Clin Cancer Res"},{"key":"5692_CR31","doi-asserted-by":"publisher","first-page":"5776","DOI":"10.4049\/jimmunol.1103201","volume":"188","author":"J Lin","year":"2012","unstructured":"Lin J, Zhou Z, Huo R, Xiao L, Ouyang G, Wang L et al (2012a) Cyr61 induces IL-6 production by fibroblast-like synoviocytes promoting Th17 differentiation in rheumatoid arthritis. J Immunol 188:5776\u20135784. https:\/\/doi.org\/10.4049\/jimmunol.1103201","journal-title":"J Immunol"},{"key":"5692_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00262-011-1135-y","volume":"61","author":"J Lin","year":"2012","unstructured":"Lin J, Huo R, Wang L, Zhou Z, Sun Y, Shen B et al (2012b) A novel anti-Cyr61 antibody inhibits breast cancer growth and metastasis in vivo. Cancer Immunol Immunother CII 61:677\u2013687. https:\/\/doi.org\/10.1007\/s00262-011-1135-y","journal-title":"Cancer Immunol Immunother CII"},{"issue":"1","key":"5692_CR33","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1038\/s41598-020-58642-y","volume":"10","author":"W Liu","year":"2020","unstructured":"Liu W, Lu X, Shi P, Yang G, Zhou Z, Li W, Mao X, Jiang D, Chen C (2020) TNF-\u03b1 increases breast cancer stem-like cells through up-regulating TAZ expression via the non-canonical NF-\u03baB pathway. Sci Rep 10(1):1804. https:\/\/doi.org\/10.1038\/s41598-020-58642-y","journal-title":"Sci Rep"},{"issue":"2","key":"5692_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1002\/j.1875-9114.1993.tb02695.x","volume":"13","author":"BL Lum","year":"1993","unstructured":"Lum BL, Gosland MP, Kaubisch S, Sikic BI (1993) Molecular targets in oncology: implications of the multidrug resistance gene. Pharmacotherapy 13(2):88\u2013109. https:\/\/doi.org\/10.1002\/j.1875-9114.1993.tb02695.x","journal-title":"Pharmacotherapy"},{"issue":"12","key":"5692_CR35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1182\/blood-2015-07-657403","volume":"127","author":"MR Luskin","year":"2016","unstructured":"Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, Lazarus HM, Levine RL, Litzow MR, Paietta EM et al (2016) Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood 127(12):1551\u20131558. https:\/\/doi.org\/10.1182\/blood-2015-07-657403","journal-title":"Blood"},{"issue":"2","key":"5692_CR36","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185\u2013229. https:\/\/doi.org\/10.1124\/pr.56.2.6","journal-title":"Pharmacol Rev"},{"issue":"5","key":"5692_CR37","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/emboj.2009.1","volume":"28","author":"T Panaretakis","year":"2009","unstructured":"Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC, Durchschlag M, Joza N, Pierron G, van Endert P et al (2009) Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 28(5):578\u2013590. https:\/\/doi.org\/10.1038\/emboj.2009.1","journal-title":"EMBO J"},{"issue":"5","key":"5692_CR38","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1128\/MCB.24.5.1823-1835.2004","volume":"24","author":"GR Panta","year":"2004","unstructured":"Panta GR, Kaur S, Cavin LG, Cort\u00e9s ML, Mercurio F, Lothstein L, Sweatman TW, Israel M, Arsura M (2004) ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK\/extracellular signal-regulated kinase\/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol Cell Biol 24(5):1823\u20131835. https:\/\/doi.org\/10.1128\/MCB.24.5.1823-1835.2004","journal-title":"Mol Cell Biol"},{"issue":"2","key":"5692_CR39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.canlet.2015.02.008","volume":"360","author":"C Riganti","year":"2015","unstructured":"Riganti C, Gazzano E, Gulino GR, Volante M, Ghigo D, Kopecka J (2015) Two repeated low doses of doxorubicin are more effective than a single high dose against tumors overexpressing P-glycoprotein. Cancer Lett 360(2):219\u2013226. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.008","journal-title":"Cancer Lett"},{"issue":"1","key":"5692_CR40","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/jbmr.535","volume":"27","author":"AA Sabile","year":"2012","unstructured":"Sabile AA, Arlt MJ, Muff R, Bode B, Langsam B, Bertz J, Jentzsch T, Puskas GJ, Born W, Fuchs B (2012) Cyr61 expression in osteosarcoma indicates poor prognosis and promotes intratibial growth and lung metastasis in mice. J Bone Miner Res 27(1):58\u201367. https:\/\/doi.org\/10.1002\/jbmr.535","journal-title":"J Bone Miner Res"},{"issue":"8","key":"5692_CR41","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1111\/cas.14083","volume":"110","author":"Y Song","year":"2019","unstructured":"Song Y, Lin Q, Cai Z, Hao T, Zhang Y, Zhu X (2019) Cysteine-rich protein 61 regulates the chemosensitivity of chronic myeloid leukemia to imatinib mesylate through the nuclear factor kappa B\/Bcl-2 pathway. Cancer Sci 110(8):2421\u20132430. https:\/\/doi.org\/10.1111\/cas.14083","journal-title":"Cancer Sci"},{"issue":"3","key":"5692_CR42","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/aja.2011.149","volume":"14","author":"N Terada","year":"2012","unstructured":"Terada N, Kulkarni P, Getzenberg RH (2012) Cyr61 is a potential prognostic marker for prostate cancer. Asian J Androl 14(3):405\u2013408. https:\/\/doi.org\/10.1038\/aja.2011.149","journal-title":"Asian J Androl"},{"issue":"6","key":"5692_CR43","doi-asserted-by":"publisher","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"T Terwilliger","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M (2017) Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J 7(6):e577\u2013e577. https:\/\/doi.org\/10.1038\/bcj.2017.53","journal-title":"Blood Cancer J"},{"issue":"Suppl 6","key":"5692_CR44","doi-asserted-by":"publisher","first-page":"vi222","DOI":"10.1093\/neuonc\/noy148.922","volume":"20","author":"S Tuncali","year":"2018","unstructured":"Tuncali S, Sereduk C, Fortin Ensign S, Kloss J, Sarkaria J, Loftus J, Tran N (2018) Rdna-06 A novel role of Sgef in mediating Gbm cell survival by modulating the DNA damage repair mechanism. Neuro Oncol 20(Suppl 6):vi222\u2013vi223. https:\/\/doi.org\/10.1093\/neuonc\/noy148.922. (Epub 2018 Nov 5)","journal-title":"Neuro Oncol"},{"issue":"11\u201312","key":"5692_CR45","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1007\/s10495-022-01763-8","volume":"27","author":"H Vasiyani","year":"2022","unstructured":"Vasiyani H, Mane M, Rana K, Shinde A, Roy M, Singh J, Gohel D, Currim F, Srivastava R, Singh R (2022) DNA damage induces STING mediated IL-6-STAT3 survival pathway in triple-negative breast cancer cells and decreased survival of breast cancer patients. Apoptosis 27(11\u201312):961\u2013978. https:\/\/doi.org\/10.1007\/s10495-022-01763-8","journal-title":"Apoptosis"},{"issue":"17","key":"5692_CR46","doi-asserted-by":"publisher","first-page":"14187","DOI":"10.1074\/jbc.M009755200","volume":"276","author":"D Xie","year":"2001","unstructured":"Xie D, Miller CW, O\u2019Kelly J, Nakachi K, Sakashita A, Said JW, Gornbein J, Koeffler HP (2001) Breast cancer Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem 276(17):14187\u201314194. https:\/\/doi.org\/10.1074\/jbc.M009755200","journal-title":"J Biol Chem"},{"issue":"6","key":"5692_CR47","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1158\/1078-0432.ccr-0659-03","volume":"10","author":"D Xie","year":"2004","unstructured":"Xie D, Yin D, Wang HJ, Liu GT, Elashoff R, Black K, Koeffler HP (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10(6):2072\u20132081. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0659-03","journal-title":"Clin Cancer Res"},{"key":"5692_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.939002","volume":"9","author":"MX Yao","year":"2022","unstructured":"Yao MX, Cheng JY, Liu Y, Sun J, Hua DX, He QY, Liu HY, Fu L, Zhao H (2022) Cross-sectional and longitudinal associations of serum cysteine-rich 61 with severity and prognosis among community-acquired pneumonia patients in China. Front Med (lausanne) 9:939002. https:\/\/doi.org\/10.3389\/fmed.2022.939002","journal-title":"Front Med (lausanne)"},{"key":"5692_CR49","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1002\/art.24999","volume":"60","author":"Q Zhang","year":"2009","unstructured":"Zhang Q, Wu J, Cao Q, Xiao L, Wang L, He D et al (2009) A critical role of Cyr61 in interleukin-17-dependent proliferation of fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Rheum 60:3602\u20133612. https:\/\/doi.org\/10.1002\/art.24999","journal-title":"Arthritis Rheum"},{"issue":"1","key":"5692_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12951-021-00922-4","volume":"19","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Jiang D, Sun X, Mo Q, Chen S, Chen W, Gui R, Ma X (2021) Biomimetic nanotherapy: core-shell structured nanocomplexes based on the neutrophil membrane for targeted therapy of lymphoma. J Nanobiotechnol 19(1):179. https:\/\/doi.org\/10.1186\/s12951-021-00922-4","journal-title":"J Nanobiotechnol"},{"key":"5692_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.2645","author":"C Zhong","year":"2017","unstructured":"Zhong C, Huo R, Hu K, Shen J, Li D, Li N et al (2017) Molecular basis for the recognition of CCN1 by monoclonal antibody 093G9. J Mol Recogn JMR. https:\/\/doi.org\/10.1002\/jmr.2645","journal-title":"J Mol Recogn JMR"},{"key":"5692_CR52","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3892\/ijo.2018.4299","volume":"52","author":"W Zhong","year":"2018","unstructured":"Zhong W, Xu X, Zhu Z, Yang L, Du H, Xia Z et al (2018) Increased interleukin-17A levels promote rituximab resistance by suppressing p53 expression and predict an unfavorable prognosis in patients with diffuse large B cell lymphoma. Int J Oncol 52:1528\u20131538. https:\/\/doi.org\/10.3892\/ijo.2018.4299","journal-title":"Int J Oncol"},{"key":"5692_CR53","doi-asserted-by":"publisher","first-page":"34018","DOI":"10.1038\/srep34018","volume":"6","author":"X Zhu","year":"2016","unstructured":"Zhu X, Song Y, Wu C, Pan C, Lu P, Wang M, Zheng P, Huo R, Zhang C, Li W et al (2016) Cyr61 participates in the pathogenesis of acute lymphoblastic leukemia by enhancing cellular survival via the AKT\/NF-kappaB signaling pathway. Sci Rep 6:34018. https:\/\/doi.org\/10.1038\/srep34018","journal-title":"Sci Rep"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05692-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05692-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T07:11:39Z","timestamp":1712992299000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05692-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["5692"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05692-8","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]},"assertion":[{"value":"24 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"159"}}